Human genetic engineering is coming. We must discuss the social and political implications now
By Samira Kiani,
The Globe and Mail
| 05. 06. 2022
photo by the He Lab
In October, 2018, I was invited to a secret meeting in Guangzhou, China. I was there because of my work as a genetic scientist who uses the CRISPR technology to cut and splice DNA, an approach to genetic engineering that has come to the forefront over the past decade. I don’t think it’s an overstatement to say that CRISPR, a precise and efficient tool that allows us to “edit” genes, is on the verge of altering the course of human history to an extent far greater than the recent “disruptions” catalyzed by internet technology. If you think digital surveillance tools are frightening in the hands of autocracy, consider the power to bend the human genome to one’s will. CRISPR provides that power. To use another analogy, the ability to edit genes with surgical precision is a scientific discovery on par with nuclear fission – while there may be beneficial applications, it is by nature seductive to our darkest impulses.
Because of CRISPR’s unknown risks, its use has been limited to certain applications by longstanding consensus...
Related Articles
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Miguel Muñoz, Cadena SER | 08.04.2026
"Para ellos, una familia numerosa no solo es una preferencia personal, sino que es una obligación. Creen que tener tantos hijos como sea posible es necesario para evitar un futuro apocalíptico", aseguraba Xavier Orri, periodista y cofundador de Página Internacional...
By Ryan Knutson and Jessica Mendoza, The Journal. | 03.27.2026
Genetically engineered babies are banned in the U.S. But that isn’t stopping Silicon Valley tech titans from trying to make one. In this final installment from The Journal’s investigation into the fringes of the fertility industry, WSJ’s Emily Glazer reports...
By Antonio Regalado, MIT Technology Review | 03.30.2026
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to create nonsentient monkey “organ sacks” as an alternative to animal testing.
In...